v3.25.2
REDEEMABLE NONCONTROLLING INTERESTS IN EQUITY OF CONSOLIDATED SUBSIDIARIES
 6 Months Ended
Jun. 30, 2025
Noncontrolling Interest [Abstract]  
REDEEMABLE NONCONTROLLING INTERESTS IN EQUITY OF CONSOLIDATED SUBSIDIARIES REDEEMABLE NONCONTROLLING INTERESTS IN EQUITY OF CONSOLIDATED SUBSIDIARIES
Certain of our investees’ partnership and operating agreements contain terms that, upon the occurrence of specified events, could obligate us to purchase some or all of the noncontrolling interests related to our consolidated subsidiaries. The noncontrolling interests subject to these provisions, and the income available to those interests, are not included as part of our equity and are presented as redeemable noncontrolling interests in the accompanying Condensed Consolidated Balance Sheets at June 30, 2025 and December 31, 2024.
The following table presents the changes in redeemable noncontrolling interests in equity of consolidated subsidiaries:
 Six Months Ended June 30,
 20252024
Balances at beginning of period $2,727 $2,391 
Net income250 222 
Distributions paid to noncontrolling interests(202)(175)
Purchases and sales of businesses and noncontrolling interests, net51 375 
Balances at end of period $2,826 $2,813 
The following tables present the composition by segment of our redeemable noncontrolling interests balances, as well as our net income available to redeemable noncontrolling interests:
 June 30, 2025December 31, 2024
Hospital Operations$853 $800 
Ambulatory Care1,973 1,927 
Redeemable noncontrolling interests$2,826 $2,727 
 Six Months Ended June 30,
 20252024
Hospital Operations$54 $53 
Ambulatory Care196 169 
Net income available to redeemable noncontrolling interests$250 $222 
In June 2022, we entered into a share purchase agreement to acquire the 5% ownership interest then-held by Baylor University Medical Center in USPI for $406 million. Under the share purchase agreement, we were obligated to make non‑interest-bearing monthly payments through June 2025. We repaid the outstanding balance under the share purchase agreement in full during the three months ended June 30, 2025. At December 31, 2024, the remaining obligation under the share purchase agreement of $68 million was included in other current liabilities in the accompanying Condensed Consolidated Balance Sheet.